Search Results

You are looking at 81 - 90 of 791 items for :

  • "metastases" x
  • Refine by Access: All x
Clear All
Full access

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi Kumar, Georgia Litsas, Rana McKay, Donald A. Podoloff, Sandy Srinivas, and Catherine H. Van Poznak

prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors at a dose of 120 mg monthly 115 , 116 ( Table 2 ). Estrogen/Hormonal Therapy: Estrogen is an antiresorptive with proven antifracture efficacy, as demonstrated

Full access

Héctor G. van den Boorn, Willemieke P.M. Dijksterhuis, Lydia G.M. van der Geest, Judith de Vos-Geelen, Marc G. Besselink, Johanna W. Wilmink, Martijn G.H. van Oijen, and Hanneke W.M. van Laarhoven

-making becomes increasingly important in clinical practice. 26 In patients with PDAC and metastases at initial diagnosis, median overall survival (OS) in the real-world setting (ie, outside of clinical trials) ranges from 2.3 to 5.9 months in patients who

Full access

Andrea Maurichi, Rosalba Miceli, Roberto Patuzzo, Francesco Barretta, Gianfranco Gallino, Ilaria Mattavelli, Consuelo Barbieri, Andrea Leva, Umberto Cortinovis, Elena Tolomio, Milena Sant, Gianpiero Castelli, Leonardo Zichichi, Giovanni Pellacani, Ignazio Stanganelli, Marco Simonacci, Ausilia Manganoni, Corrado Del Forno, Gioachino Caresana, Catherine Harwood, Daniele Bergamaschi, Konstantinos Lasithiotakis, Dorothy Bennett, Vittoria Espeli, Cristina Mangas, Sandra Leoni Parvex, Barbara Valeri, Mara Cossa, Marta Barisella, Alessandro Pellegrinelli, Claudia Miranda, Andrea Anichini, Roberta Mortarini, Odysseas Zoras, and Mario Santinami

local recurrences, 43 regional recurrences, and 8 distant metastases as first events. Six patients died as a result of disease progression. Of the patients who developed regional recurrences, 34 (79.1%) had not undergone SNB, 6 (13.9%) underwent SNB and

Full access

Richard L. Theriault, J. Sybil Biermann, Elizabeth Brown, Adam Brufsky, Laurence Demers, Ravinder K. Grewal, Theresa Guise, Rebecca Jackson, Kevin McEnery, Donald Podoloff, Peter Ravdin, Charles L. Shapiro, Matthew Smith, and Catherine H. Van Poznak

, therapeutic strategies to maintain bone health, and treatment of bone metastases, including surgery for pathologic fractures. Multiple members of the health care team may be needed for effective patient care and education. This report summarizes presentations

Full access

Rishi Agarwal, Jiang Wang, Keith Wilson, William Barrett, and John C. Morris

identify potential therapies that may have clinical merit. Figure 3. (A,B) Baseline chest CT demonstrating pulmonary metastases. (C,D) CT imaging after 2 months of treatment with dabrafenib and trametinib demonstrating tumor regression. (E,F) CT

Full access

NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021

Featured Updates to the NCCN Guidelines

Susan M. Swetter, John A. Thompson, Mark R. Albertini, Christopher A. Barker, Joel Baumgartner, Genevieve Boland, Bartosz Chmielowski, Dominick DiMaio, Alison Durham, Ryan C. Fields, Martin D. Fleming, Anjela Galan, Brian Gastman, Kenneth Grossmann, Samantha Guild, Ashley Holder, Douglas Johnson, Richard W. Joseph, Giorgos Karakousis, Kari Kendra, Julie R. Lange, Ryan Lanning, Kim Margolin, Anthony J. Olszanski, Patrick A. Ott, Merrick I. Ross, April K. Salama, Rohit Sharma, Joseph Skitzki, Jeffrey Sosman, Evan Wuthrick, Nicole R. McMillian, and Anita M. Engh

Staging and Treatment of Cutaneous Melanoma Cutaneous melanomas are categorized as follows: localized disease with no evidence of regional or distant metastases (stages 0–II), regional nodal/in-transit disease (stage III), and distant metastatic disease

Full access

Zeynep Eroglu, Odicie Fielder, and George Somlo

with higher numbers noted in those with multiple bone metastases. 28 In a retrospective analysis of 151 patients with metastatic breast cancer, baseline CTC levels of 5 or greater CTCs per 7.5 mL of blood using CellSearch were prognostic for decreased

Full access

Elio Mazzone, Sophie Knipper, Francesco A. Mistretta, Carlotta Palumbo, Zhe Tian, Andrea Gallina, Derya Tilki, Shahrokh F. Shariat, Francesco Montorsi, Fred Saad, Alberto Briganti, and Pierre I. Karakiewicz

teaching hospitals (68.1% vs 57.4%; P =.005), and to patients with liver metastases (20.4% vs 10.0%; P <.001). According to principal diagnosis at admission, IPC services were more frequently used in patients admitted for infections (23.0% vs 11.9%; P

Full access

Darren Sigal, Marie Tartar, Marin Xavier, Fei Bao, Patrick Foley, David Luo, Jason Christiansen, Zachary Hornby, Edna Chow Maneval, and Pratik Multani

distribution of disease, demonstrating the extensive skeletal metastases and bulky pelvic lymphadenopathy. (B) Octreoscan (ant and post, planar) after 6 cycles of entrectinib shows significant burden of disease, including in the liver, bones, and pelvis, but

Full access

Lirong Liu, Fangfang Hou, Yufeng Liu, Wenzhu Li, and Haibo Zhang

hypermetabolic nodules in left hilar suggestive of lung cancer with obstructive pneumonia and bone and right adrenal metastases. (B1–B3) CT after 2 cycles of carboplatin/pemetrexed with bevacizumab shows left lower lobe atelectasis aggravated with a large